Page last updated: 2024-12-05

3,5-dichlorosalicylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,5-Dichlorosalicylic acid (3,5-DClSA) is a synthetic organic compound. It is a derivative of salicylic acid with chlorine atoms at the 3 and 5 positions. It is a white, crystalline solid that is soluble in ethanol and ether but sparingly soluble in water. It is typically synthesized by the chlorination of salicylic acid with chlorine gas in the presence of a catalyst such as iron. 3,5-DClSA has been studied for its potential biological activity. It has been shown to exhibit antimicrobial activity against a range of bacteria and fungi. It is also a potent inhibitor of the enzyme cyclooxygenase, which is involved in the production of prostaglandins, which are inflammatory mediators. This suggests that 3,5-DClSA could potentially be useful as an anti-inflammatory agent. However, further research is needed to investigate its safety and efficacy in humans.'
```

3,5-dichlorosalicylic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9445
CHEMBL ID449129
CHEBI ID165214
SCHEMBL ID184603
MeSH IDM0503992

Synonyms (57)

Synonym
nsc 30109
hsdb 5562
ai3-22601
einecs 206-281-8
brn 2210803
chembl449129 ,
bdbm26269
benzoic acid, 3,5-dichloro-2-hydroxy-
salicylic acid, 3,5-dichloro-
3,5-dichloro-2-hydroxy-benzoic acid
320-72-9
2-hydroxy-3,5-dichlorobenzoic acid
benzoic acid,5-dichloro-2-hydroxy-
nsc30109
nsc-30109
3,5-dichloro-2-hydroxybenzoic acid
usaf do-68
3,5-dichlorosalicylic acid
wln: qvr bq cg eg
salicylic acid,5-dichloro-
c2u ,
OPREA1_584773
STK299334
inchi=1/c7h4cl2o3/c8-3-1-4(7(11)12)6(10)5(9)2-3/h1-2,10h,(h,11,12
3,5-dichlorosalicylic acid, 97%
AC-11775
AKOS000459994
CHEBI:165214
3,5-dichlorosalicylicacid
D1112
tox21_301696
dtxsid3044914 ,
dtxcid1024914
NCGC00256066-01
cas-320-72-9
A821116
3,5-dichlorosalicyclic acid
unii-o6pxr32g3v
4-10-00-00213 (beilstein handbook reference)
o6pxr32g3v ,
FT-0614578
BBL025712
PS-4183
SCHEMBL184603
2-hydroxy-3,5-dichlorobenzoic acid [hsdb]
mfcd00002442
SY018904
J-018623
106086-54-8
CS-W021812
3.5-dichlorosalicylic acid
HMS3741A07
Q27285414
salicylic acid, 3,5-dichloro- (6ci,7ci,8ci); 3,5-dichloro-2-hydroxybenzoic acid; 2-hydroxy-3,5-dichlorobenzoic acid; nsc 30109
EN300-91872
Z111571460
PD128446
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
chlorobenzoic acidAny member of the class of benzoic acids in which the benzene ring is substituted by at least one chloro group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency68.58960.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency40.10890.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency61.13060.000221.22318,912.5098AID1259243
estrogen nuclear receptor alphaHomo sapiens (human)Potency29.21560.000229.305416,493.5996AID743069; AID743078
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency61.13060.000323.4451159.6830AID743065
histone deacetylase 9 isoform 3Homo sapiens (human)Potency48.55770.037617.082361.1927AID1259364
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aldo-keto reductase family 1 member C4Homo sapiens (human)Ki16.14320.00590.54812.8000AID1798661; AID342626
Aldo-keto reductase family 1 member C3Homo sapiens (human)Ki23.92100.00590.70913.1000AID1798661; AID342625
Aldo-keto reductase family 1 member A1Sus scrofa (pig)IC50 (µMol)11.30000.00051.66804.0000AID367704
Aldo-keto reductase family 1 member C2 Homo sapiens (human)Ki12.14290.00590.37312.8000AID1798661; AID342624; AID536803
Aldo-keto reductase family 1 member C1Homo sapiens (human)IC50 (µMol)0.00600.00603.12657.9000AID350176
Aldo-keto reductase family 1 member C1Homo sapiens (human)Ki7.07750.00590.56752.8000AID1798661; AID342619; AID342620; AID342621; AID342622; AID342623; AID536798; AID536799; AID536800; AID591009; AID591010
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (40)

Processvia Protein(s)Taxonomy
retinoid metabolic processAldo-keto reductase family 1 member C4Homo sapiens (human)
bile acid biosynthetic processAldo-keto reductase family 1 member C4Homo sapiens (human)
steroid metabolic processAldo-keto reductase family 1 member C4Homo sapiens (human)
androgen metabolic processAldo-keto reductase family 1 member C4Homo sapiens (human)
bile acid and bile salt transportAldo-keto reductase family 1 member C4Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member C4Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member C4Homo sapiens (human)
cellular response to jasmonic acid stimulusAldo-keto reductase family 1 member C4Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member C4Homo sapiens (human)
progesterone metabolic processAldo-keto reductase family 1 member C4Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
G protein-coupled receptor signaling pathwayAldo-keto reductase family 1 member C3Homo sapiens (human)
response to nutrientAldo-keto reductase family 1 member C3Homo sapiens (human)
steroid metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
positive regulation of cell population proliferationAldo-keto reductase family 1 member C3Homo sapiens (human)
male gonad developmentAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to starvationAldo-keto reductase family 1 member C3Homo sapiens (human)
farnesol catabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
cyclooxygenase pathwayAldo-keto reductase family 1 member C3Homo sapiens (human)
keratinocyte differentiationAldo-keto reductase family 1 member C3Homo sapiens (human)
progesterone metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
retinal metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
macromolecule metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
regulation of retinoic acid receptor signaling pathwayAldo-keto reductase family 1 member C3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionAldo-keto reductase family 1 member C3Homo sapiens (human)
testosterone biosynthetic processAldo-keto reductase family 1 member C3Homo sapiens (human)
renal absorptionAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to calcium ionAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to prostaglandin stimulusAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to corticosteroid stimulusAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to jasmonic acid stimulusAldo-keto reductase family 1 member C3Homo sapiens (human)
cellular response to prostaglandin D stimulusAldo-keto reductase family 1 member C3Homo sapiens (human)
negative regulation of retinoic acid biosynthetic processAldo-keto reductase family 1 member C3Homo sapiens (human)
regulation of testosterone biosynthetic processAldo-keto reductase family 1 member C3Homo sapiens (human)
positive regulation of endothelial cell apoptotic processAldo-keto reductase family 1 member C3Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
G protein-coupled receptor signaling pathwayAldo-keto reductase family 1 member C2 Homo sapiens (human)
digestionAldo-keto reductase family 1 member C2 Homo sapiens (human)
steroid metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
positive regulation of cell population proliferationAldo-keto reductase family 1 member C2 Homo sapiens (human)
epithelial cell differentiationAldo-keto reductase family 1 member C2 Homo sapiens (human)
progesterone metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member C2 Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionAldo-keto reductase family 1 member C2 Homo sapiens (human)
cellular response to jasmonic acid stimulusAldo-keto reductase family 1 member C2 Homo sapiens (human)
cellular response to prostaglandin D stimulusAldo-keto reductase family 1 member C2 Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
xenobiotic metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
digestionAldo-keto reductase family 1 member C1Homo sapiens (human)
bile acid metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
bile acid and bile salt transportAldo-keto reductase family 1 member C1Homo sapiens (human)
intestinal cholesterol absorptionAldo-keto reductase family 1 member C1Homo sapiens (human)
epithelial cell differentiationAldo-keto reductase family 1 member C1Homo sapiens (human)
progesterone metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
retinal metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
cholesterol homeostasisAldo-keto reductase family 1 member C1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
response to organophosphorusAldo-keto reductase family 1 member C1Homo sapiens (human)
cellular response to jasmonic acid stimulusAldo-keto reductase family 1 member C1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member C1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (35)

Processvia Protein(s)Taxonomy
retinal dehydrogenase activityAldo-keto reductase family 1 member C4Homo sapiens (human)
aldo-keto reductase (NADPH) activityAldo-keto reductase family 1 member C4Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activityAldo-keto reductase family 1 member C4Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member C4Homo sapiens (human)
bile acid transmembrane transporter activityAldo-keto reductase family 1 member C4Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptorAldo-keto reductase family 1 member C4Homo sapiens (human)
dihydrotestosterone 17-beta-dehydrogenase activityAldo-keto reductase family 1 member C4Homo sapiens (human)
androsterone dehydrogenase activityAldo-keto reductase family 1 member C4Homo sapiens (human)
5alpha-androstane-3beta,17beta-diol dehydrogenase activityAldo-keto reductase family 1 member C4Homo sapiens (human)
testosterone dehydrogenase (NAD+) activityAldo-keto reductase family 1 member C4Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activityAldo-keto reductase family 1 member C4Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C4Homo sapiens (human)
chlordecone reductase activityAldo-keto reductase family 1 member C4Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member C4Homo sapiens (human)
ketosteroid monooxygenase activityAldo-keto reductase family 1 member C4Homo sapiens (human)
bile acid bindingAldo-keto reductase family 1 member C4Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
aldo-keto reductase (NADPH) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activityAldo-keto reductase family 1 member C3Homo sapiens (human)
all-trans-retinol dehydrogenase (NAD+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptorAldo-keto reductase family 1 member C3Homo sapiens (human)
phenanthrene 9,10-monooxygenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
dihydrotestosterone 17-beta-dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin D2 11-ketoreductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
geranylgeranyl reductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
ketoreductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
prostaglandin-F synthase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
15-hydroxyprostaglandin-D dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
androsterone dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
5alpha-androstane-3beta,17beta-diol dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
testosterone dehydrogenase (NAD+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
ketosteroid monooxygenase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
Delta4-3-oxosteroid 5beta-reductase activityAldo-keto reductase family 1 member C3Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C3Homo sapiens (human)
bile acid bindingAldo-keto reductase family 1 member C3Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptorAldo-keto reductase family 1 member C2 Homo sapiens (human)
phenanthrene 9,10-monooxygenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
carboxylic acid bindingAldo-keto reductase family 1 member C2 Homo sapiens (human)
bile acid bindingAldo-keto reductase family 1 member C2 Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
ketosteroid monooxygenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
indanol dehydrogenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
androsterone dehydrogenase activityAldo-keto reductase family 1 member C2 Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member C1Homo sapiens (human)
aldo-keto reductase (NADPH) activityAldo-keto reductase family 1 member C1Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activityAldo-keto reductase family 1 member C1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member C1Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptorAldo-keto reductase family 1 member C1Homo sapiens (human)
phenanthrene 9,10-monooxygenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
testosterone dehydrogenase [NAD(P)] activityAldo-keto reductase family 1 member C1Homo sapiens (human)
carboxylic acid bindingAldo-keto reductase family 1 member C1Homo sapiens (human)
bile acid bindingAldo-keto reductase family 1 member C1Homo sapiens (human)
3beta-hydroxy-5beta-steroid dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptorAldo-keto reductase family 1 member C1Homo sapiens (human)
dihydrotestosterone 17-beta-dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
5alpha-androstane-3beta,17beta-diol dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
androsterone dehydrogenase (B-specific) activityAldo-keto reductase family 1 member C1Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activityAldo-keto reductase family 1 member C1Homo sapiens (human)
ketosteroid monooxygenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
indanol dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
androsterone dehydrogenase activityAldo-keto reductase family 1 member C1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
cytoplasmAldo-keto reductase family 1 member C4Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C4Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member C4Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C4Homo sapiens (human)
nucleusAldo-keto reductase family 1 member C3Homo sapiens (human)
cytoplasmAldo-keto reductase family 1 member C3Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C3Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member C3Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C3Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C2 Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member C1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member C1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (43)

Assay IDTitleYearJournalArticle
AID1145607Octanol-aqueous phase distribution coefficient, log D of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID536801Selectivity ratio of Ki for human AKR1C1 Leu308Val mutant to Ki for human wild type AKR1C12010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structure-based optimization and biological evaluation of human 20α-hydroxysteroid dehydrogenase (AKR1C1) salicylic acid-based inhibitors.
AID1145615Dissociation constant, pKa of the compound at pH 7.81977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID342633Ratio of Ki for human recombinant AKR1C4 to Ki for human recombinant AKR1C12008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid.
AID342630Ratio of Ki for human recombinant 20-alpha-hydroxysteroid dehydrogenase Leu308Ala mutant to Ki for human recombinant AKR1C12008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid.
AID342627Ratio of Ki for human recombinant 20-alpha-hydroxysteroid dehydrogenase Leu54Val mutant to Ki for human recombinant AKR1C12008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid.
AID342621Inhibition of human recombinant 20-alpha-hydroxysteroid dehydrogenase His222Ser mutant2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid.
AID1144132Increase in mollusk membrane potential assessed as concentration required to raise 20 mV1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
On the structure of medicinal chemistry.
AID1145614Dissociation constant, pKa of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID342620Inhibition of human recombinant 20-alpha-hydroxysteroid dehydrogenase Leu54Val mutant2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid.
AID342631Ratio of Ki for human recombinant AKR1C2 to Ki for human recombinant AKR1C12008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid.
AID536803Inhibition of human AKR1C2 dehydrogenase activity by fluorometric assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structure-based optimization and biological evaluation of human 20α-hydroxysteroid dehydrogenase (AKR1C1) salicylic acid-based inhibitors.
AID536802Selectivity ratio of Ki for human AKR1C1 Leu308Ala mutant to Ki for human wild type AKR1C12010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structure-based optimization and biological evaluation of human 20α-hydroxysteroid dehydrogenase (AKR1C1) salicylic acid-based inhibitors.
AID342625Inhibition of human recombinant AKR1C32008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid.
AID591009Competitive inhibition of human recombinant AKR1C1 Phe311Leu mutant by fluorescence assay2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Probing the inhibitor selectivity pocket of human 20α-hydroxysteroid dehydrogenase (AKR1C1) with X-ray crystallography and site-directed mutagenesis.
AID350179Selectivity ratio of Ki for human type 1 3-alpha-HSD to Ki for human 20-alpha HSD2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Structure-guided design, synthesis, and evaluation of salicylic acid-based inhibitors targeting a selectivity pocket in the active site of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1).
AID342622Inhibition of human recombinant 20-alpha-hydroxysteroid dehydrogenase Leu306Ala mutant2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid.
AID342624Inhibition of human recombinant AKR1C22008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid.
AID536798Inhibition of human wild type AKR1C1 dehydrogenase activity by fluorometric assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structure-based optimization and biological evaluation of human 20α-hydroxysteroid dehydrogenase (AKR1C1) salicylic acid-based inhibitors.
AID591006Binding affinity to human AKR1C1 after 4 hrs by crystallography2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Probing the inhibitor selectivity pocket of human 20α-hydroxysteroid dehydrogenase (AKR1C1) with X-ray crystallography and site-directed mutagenesis.
AID342619Inhibition of human recombinant 20-alpha-hydroxysteroid dehydrogenase2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid.
AID367704Inhibition of pig ALR12009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase.
AID536800Inhibition of human AKR1C1 Leu308Ala mutant dehydrogenase activity by fluorometric assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structure-based optimization and biological evaluation of human 20α-hydroxysteroid dehydrogenase (AKR1C1) salicylic acid-based inhibitors.
AID342623Inhibition of human recombinant 20-alpha-hydroxysteroid dehydrogenase Leu308Ala mutant2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid.
AID350176Inhibition of 20-alpha HSD2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Structure-guided design, synthesis, and evaluation of salicylic acid-based inhibitors targeting a selectivity pocket in the active site of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1).
AID1145605Octanol-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID367705Inhibition of human recombinant ALR2 expressed in bacterial cell expression system2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase.
AID591010Competitive inhibition of human recombinant AKR1C1 Phe311Ala mutant by fluorescence assay2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Probing the inhibitor selectivity pocket of human 20α-hydroxysteroid dehydrogenase (AKR1C1) with X-ray crystallography and site-directed mutagenesis.
AID536799Inhibition of human AKR1C1 Leu308Val mutant dehydrogenase activity by fluorometric assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structure-based optimization and biological evaluation of human 20α-hydroxysteroid dehydrogenase (AKR1C1) salicylic acid-based inhibitors.
AID342632Ratio of Ki for human recombinant AKR1C3 to Ki for human recombinant AKR1C12008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid.
AID350178Selectivity ratio of Ki for human type 2 3-alpha-HSD to Ki for human 20-alpha HSD2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Structure-guided design, synthesis, and evaluation of salicylic acid-based inhibitors targeting a selectivity pocket in the active site of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1).
AID367709Inhibition of pig ALR1 by mixed inhibition based Lineweaver-Burke plot2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase.
AID591015Ratio of Ki for human recombinant AKR1C1 Phe311Leu mutant to Ki for human wild-type AKR1C12011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Probing the inhibitor selectivity pocket of human 20α-hydroxysteroid dehydrogenase (AKR1C1) with X-ray crystallography and site-directed mutagenesis.
AID591016Ratio of Ki for human recombinant AKR1C1 Phe311Ala mutant to Ki for human wild-type AKR1C12011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Probing the inhibitor selectivity pocket of human 20α-hydroxysteroid dehydrogenase (AKR1C1) with X-ray crystallography and site-directed mutagenesis.
AID1145616Increase in membrane potential in mollusc neurons assessed as conductance of potassium at pH 7.8 relative to salicylic acid1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID367703Inhibition of human recombinant ALR2 expressed in bacterial cell expression system by Uncompetitive inhibition based Lineweaver-Burke plot2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase.
AID367706Selectivity ratio of IC50 for human recombinant ALR2 to IC50 for pig ALR12009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase.
AID342629Ratio of Ki for human recombinant 20-alpha-hydroxysteroid dehydrogenase Leu306Ala mutant to Ki for human recombinant AKR1C12008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid.
AID1144131Lipophilicity, log P of the compound1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
On the structure of medicinal chemistry.
AID342628Ratio of Ki for human recombinant 20-alpha-hydroxysteroid dehydrogenase His222Ser mutant to Ki for human recombinant AKR1C12008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid.
AID536804Selectivity ratio of Ki for human AKR1C2 to Ki for human AKR1C12010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structure-based optimization and biological evaluation of human 20α-hydroxysteroid dehydrogenase (AKR1C1) salicylic acid-based inhibitors.
AID342626Inhibition of human recombinant AKR1C42008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid.
AID1798661Assay of Enzyme Activity from Article 10.1021/jm8003575: \\Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosa2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (16.67)18.7374
1990's0 (0.00)18.2507
2000's6 (50.00)29.6817
2010's4 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.12 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]